{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T14:02:59Z","timestamp":1785420179358,"version":"3.56.0"},"reference-count":38,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"AbbVie"},{"id":[{"id":"https:\/\/ror.org\/02g5p4n58","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxins"],"abstract":"<jats:p>(1) Background: While evidence supporting the use of onabotulinumtoxinA in patients with cervical dystonia (CD) is well-established, more evidence is needed to understand if onabotulinumtoxinA treatment can reduce reliance on addictive medication. (2) Methods: This retrospective study used claims data to evaluate the impact of onabotulinumtoxinA treatment on opioid, benzodiazepine (BZD), and skeletal muscle relaxant (SMR) prescription fills among patients diagnosed with CD with prior use of these medications. Among the 564 eligible patients, three non-mutually exclusive cohorts were identified based on medication use data: opioid (n = 306), BZD (n = 271), and SMR (n = 371). The follow-up period continued for 12 months after onabotulinumtoxinA treatment initiation. (3) Results: Among patients with &gt;1 opioid fill at baseline, 30.4% had no opioid fills in the 12-month period following onabotulinumtoxinA initiation. The opioid cohort had significantly reduced mean opioid prescription fills per patient (17.0%; p &lt; 0.0001) in the follow-up period compared with baseline. A 30.0% decrease was observed in the mean morphine milligram equivalent (MME)\/day after onabotulinumtoxinA initiation (p &lt; 0.0001). Similar trends of decreased BZD and SMR prescription fills were observed. (4) Conclusions: Following initiation of onabotulinumtoxinA treatment, patients living with CD who had prior opioid, BZD, or SMR use had significant reductions in respective prescription fills for opioids, BZDs, and SMRs.<\/jats:p>","DOI":"10.3390\/toxins18060269","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T08:22:56Z","timestamp":1781684576000},"page":"269","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Impact of OnabotulinumtoxinA on Oral Pain Medication Prescription Fills and Low-Value Care in Patients with Cervical Dystonia in the United States: A Retrospective Claims Analysis"],"prefix":"10.3390","volume":"18","author":[{"given":"Christopher","family":"Rhyne","sequence":"first","affiliation":[{"name":"Norton Neuroscience Institute, Louisville, KY 40202, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annaliza","family":"Dominguez","sequence":"additional","affiliation":[{"name":"AbbVie Inc., North Chicago, IL 60064, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Cheng","sequence":"additional","affiliation":[{"name":"AbbVie Inc., North Chicago, IL 60064, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivaji","family":"Manthena","sequence":"additional","affiliation":[{"name":"AbbVie Inc., North Chicago, IL 60064, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krutika","family":"Parikh","sequence":"additional","affiliation":[{"name":"AbbVie Inc., North Chicago, IL 60064, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7204-8730","authenticated-orcid":false,"given":"Bahman","family":"Jabbari","sequence":"additional","affiliation":[{"name":"Department of Neurology, Yale School of Medicine, New Haven, CT 06510, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/mds.25475","article-title":"Phenomenology and classification of dystonia: A consensus update","volume":"28","author":"Albanese","year":"2013","journal-title":"Mov. Disord."},{"key":"ref_2","first-page":"tre-03","article-title":"Descriptive epidemiology of cervical dystonia","volume":"3","author":"Defazio","year":"2013","journal-title":"Tremor Other Hyperkinet. Mov."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.parkreldis.2007.02.005","article-title":"Prevalence of cervical dystonia and spasmodic torticollis in the United States general population","volume":"13","author":"Jankovic","year":"2007","journal-title":"Park. Relat. Disord."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1002\/mds.27927","article-title":"Cervical dystonia incidence and diagnostic delay in a multiethnic population","volume":"35","author":"LaHue","year":"2020","journal-title":"Mov. Disord."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/mdc3.12238","article-title":"Impact of Cervical Dystonia on Work Productivity: An Analysis from a Patient Registry","volume":"3","author":"Molho","year":"2016","journal-title":"Mov. Disord. Clin. Pract."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.3390\/toxins7062321","article-title":"Pain Relief in Cervical Dystonia with Botulinum Toxin Treatment","volume":"7","author":"Camargo","year":"2015","journal-title":"Toxins"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1017\/cjn.2020.275","article-title":"Improvement in Quality of Life with OnabotulinumtoxinA for Cervical Dystonia: POSTURe","volume":"48","author":"Petitclerc","year":"2021","journal-title":"Can. J. Neurol. Sci."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/nrneurol.2009.196","article-title":"The clinical approach to movement disorders","volume":"6","author":"Abdo","year":"2010","journal-title":"Nat. Rev. Neurol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.parkreldis.2019.06.009","article-title":"Pain in cervical dystonia: Evidence of abnormal inhibitory control","volume":"65","author":"Tinazzi","year":"2019","journal-title":"Park. Relat. Disord."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1080\/14737175.2021.1984230","article-title":"Pain in cervical dystonia: Mechanisms, assessment and treatment","volume":"21","author":"Rosales","year":"2021","journal-title":"Expert. Rev. Neurother."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1007\/s00415-018-8840-9","article-title":"For the members of the Dystonia Coalition. Cervical dystonia and substance abuse","volume":"265","author":"Mahajan","year":"2018","journal-title":"J. Neurol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1007\/s13311-020-00944-0","article-title":"Treatment of Dystonia: Medications, Neurotoxins, Neuromodulation, and Rehabilitation","volume":"17","author":"Bledsoe","year":"2020","journal-title":"Neurotherapeutics"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s13311-013-0231-4","article-title":"Treatment of dystonia","volume":"11","author":"Thenganatt","year":"2014","journal-title":"Neurotherapeutics"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e2148599","DOI":"10.1001\/jamanetworkopen.2021.48599","article-title":"Development of a Metric to Detect and Decrease Low-Value Prescribing in Older Adults","volume":"5","author":"Radomski","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"ref_15","unstructured":"U.S. Centers for Medicare & Medicaid Services (2026, January 29). Local Coverage Determination L39857: Botulinum Toxin Injections, Available online: https:\/\/www.cms.gov\/medicare-coverage-database\/view\/lcd.aspx?lcdId=39857&ver=7."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1007\/s00415-016-8050-2","article-title":"A mixed treatment comparison to compare the efficacy and safety of botulinum toxin treatments for cervical dystonia","volume":"263","author":"Han","year":"2016","journal-title":"J. Neurol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"NS20180058","DOI":"10.1042\/NS20180058","article-title":"Therapeutic use of botulinum toxin in pain treatment","volume":"2","author":"Kumar","year":"2018","journal-title":"Neuronal Signal."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1136\/jnnp-2012-303608","article-title":"Long-term efficacy and safety of incobotulinumtoxinA injections in patients with cervical dystonia","volume":"84","author":"Dressler","year":"2013","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/mds.20403","article-title":"Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: Results of the first US randomized, double-blind, placebo-controlled study","volume":"20","author":"Truong","year":"2005","journal-title":"Mov. Disord."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3986","DOI":"10.1007\/s12325-023-02563-5","article-title":"Botulinum Toxin Utilization, Treatment Patterns, and Healthcare Costs Among Patients with Spasticity or Cervical Dystonia in the US","volume":"40","author":"Hull","year":"2023","journal-title":"Adv. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"10655","DOI":"10.3389\/dyst.2022.10655","article-title":"Botulinum Toxin in the Treatment of Cervical Dystonia: Evidence-Based Review","volume":"1","author":"Hammoud","year":"2022","journal-title":"Dystonia"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1007\/s00415-019-09349-2","article-title":"Treatment of cervical dystonia with abo- and onabotulinumtoxinA: Long-term safety and efficacy in daily clinical practice","volume":"266","author":"Jochim","year":"2019","journal-title":"J. Neurol."},{"key":"ref_23","unstructured":"Food and Drug Administration (FDA) (2026, June 09). DAXXIFY\u00ae (DaxibotulinumtoxinA-lanm) for Injection, for Intramuscular Use, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761127s002lbl.pdf."},{"key":"ref_24","unstructured":"Food and Drug Administration (FDA) (2025, October 16). Full Prescribing Information: BOTOX (OnabotulinumtoxinA), Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/103000s5236lbl.pdf."},{"key":"ref_25","unstructured":"Food and Drug Administration (FDA) (2026, June 04). Botulinum Toxin Type A (Botox), Allergan, Inc. Approval Letter, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2000\/botaller122100l.pdf?."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"108035","DOI":"10.1016\/j.toxicon.2024.108035","article-title":"Treatment response to onabotulinumtoxinA in cervical dystonia patients with anterocollis and retrocollis","volume":"248","author":"Dashtipour","year":"2024","journal-title":"Toxicon"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e207664","DOI":"10.1001\/jamanetworkopen.2020.7664","article-title":"Assessment of Physician Prescribing of Muscle Relaxants in the United States, 2005\u20132016","volume":"3","author":"Soprano","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e2434835","DOI":"10.1001\/jamanetworkopen.2024.34835","article-title":"Long-Term Use of Muscle Relaxant Medications for Chronic Pain: A Systematic Review","volume":"7","author":"Oldfield","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s40122-019-00135-6","article-title":"Stopping or Decreasing Opioid Therapy in Patients on Chronic Opioid Therapy","volume":"8","author":"Pergolizzi","year":"2019","journal-title":"Pain. Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1212\/WNL.41.7.1088","article-title":"Cervical dystonia: Clinical findings and associated movement disorders","volume":"41","author":"Jankovic","year":"1991","journal-title":"Neurology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/mds.870060206","article-title":"Idiopathic cervical dystonia: Clinical characteristics","volume":"6","author":"Chan","year":"1991","journal-title":"Mov. Disord."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1007\/s00415-014-7343-6","article-title":"Cervical dystonia and pain: Characteristics and treatment patterns from CD PROBE (Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy)","volume":"261","author":"Charles","year":"2014","journal-title":"J. Neurol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"776","DOI":"10.3390\/toxins5040776","article-title":"Continuation of long-term care for cervical dystonia at an academic movement disorders clinic","volume":"5","author":"Gill","year":"2013","journal-title":"Toxins"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Agarwal, P., Barbano, R., Moore, H., Schwartz, M., Zuzek, A., Sadeghi, M., and Patel, A. (2022). OnabotulinumtoxinA Dosing, Disease Severity, and Treatment Benefit in Patients with Cervical Dystonia: A Cohort Analysis from CD PROBE. Front. Neurol., 13.","DOI":"10.3389\/fneur.2022.914486"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Shipkov, H., Uchikov, P., Imran, A., Ul Hassan, Z., Grozdev, I., Kraev, K., Kraeva, M., Koleva, N., Bozhkova, M., and Karamitev, S. (2025). Comparing Injection Methods of Botulinum Toxin A for Cervical Dystonia: A Systematic Review. Life, 15.","DOI":"10.3390\/life15060920"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"11","DOI":"10.5334\/tohm.867","article-title":"Impact of Physiotherapy in the Treatment of Pain in Cervical Dystonia","volume":"14","author":"Jacksch","year":"2024","journal-title":"Tremor Other Hyperkinet. Mov."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"232","DOI":"10.5603\/PJNNS.a2020.0021","article-title":"Cervical dystonia\u2014Improving the effectiveness of botulinum toxin therapy","volume":"54","author":"Tyslerowicz","year":"2020","journal-title":"Neurol. Neurochir. Pol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr7103a1","article-title":"CDC Clinical Practice Guideline for Prescribing Opioids for Pain\u2014United States, 2022","volume":"71","author":"Dowell","year":"2022","journal-title":"MMWR Recomm. Rep."}],"container-title":["Toxins"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6651\/18\/6\/269\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T04:48:01Z","timestamp":1781844481000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6651\/18\/6\/269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":38,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["toxins18060269"],"URL":"https:\/\/doi.org\/10.3390\/toxins18060269","relation":{},"ISSN":["2072-6651"],"issn-type":[{"value":"2072-6651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]}}}